HealthTree for Multiple Myeloma recently posted summary results of several studies that included talquetamab as part of the clinical treatment program. Talquetamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody.
The agent targets the novel biomarker GPRC5D on multiple myeloma cells and CD3 on T-cells. On June 29, 2022 Johnson & Johnson/Janssen announced that the US Food and Drug Administration (FDA) granted talquetamab “Breakthrough therapy designation” for talquetamab.
“Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).”
The expedited approval process benefits all of us, myeloma patients, and all indications are that this new product will arrive into clinical practice in a few months.
